J Lipid Atheroscler.  2012 Dec;1(2):45-59. 10.12997/jla.2012.1.2.45.

Treatment Guidelines for Dyslipidemia: Summary of the Expanded Second Version

• Son JI
• Chin SO
• Woo JT
• The Committee for Developing Treatment Guidelines for Dyslipidemia, Korean Society of Lipidology and Atherosclerosis (KSLA)

• KMID: 2198362
• DOI: http://doi.org/10.12997/jla.2012.1.2.45

Abstract

KSLA published our first version of treatment guidelines for dyslipidemia in 1996, which was based on health examination data gathered by the National Health Insurance Corperation in 1994. A number of academic societies including the Korean Endocrine Society, the Korean Society of Cardiology, the Korean Society for Laboratory Medicine, the Korean Society for Biochemistry and the Korean Nutrition Society participated in the development of this guideline. In 2003, the second version of our guidelines was published based on the Korean National Health and Nutrition Survey (KNHANES) data which was collected in 1998. In 2006, the second version was modified and expanded with using KNHANES data collected in 2005. This article summarizes the recommendations included in the expanded second version of treatment guidelines. The full version of treatment guidelines in Korean is available at the KSLA Homepage (http://www.lipid.or.kr).

Keyword

Dyslipidemia; Treatment; Guideline

MeSH Terms

Biochemistry
Cardiology
Dyslipidemias
National Health Programs
Nutrition Surveys

Figure

• 

  Fig. 1. Relative risk of ischemic heart disease associated with LDL(A) and HDL(B) cholesterol.

Reference

1. Avoiding heart Attacks and Strokes. World Health Organization; [accessed 2007 January 16]. 2005. Available from: URL: http://www.who.int/cardiovascular_diseases/resources/cvd_report.pdf.

2. Cause of death statistics. Statistics Korea; 2004.

3. Jee SH, Park JW, Lee SY, Nam BH, Ryu HG, Kim SY, Kim YN, Lee JK, Choi SM, Yun JE. Stroke risk prediction model: a risk profile from the Korean study. Atherosclerosis. 2008; 197(1):318–325.

4. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004; 110:227–239.

5. Executive summary of Japan Atherosclerosis Society Guideline for diagnosis and prevention of atherosclerotic cardiovascular disease for Japanese. J Atheroscler Thromb. 2007; 14:45–50.

6. Jun KR, Park HI, Chun S, Park H, Min WK. Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula. Clin Chem Lab Med. 2008; 46:371–375.

7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502.

8. National Institutes of Health, National Heart, Lung, and Blood Institute. Third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. 2002. NIH Publication No. 02-5215.

9. Weggemans RM, Zock PL, Katan MB. Dietary cholesterol from eggs increases the ratio of total cholesterol to HDL Cholesterol in humans: a meta-analysis. Am J Clin Nutr. 2001; 73:885–891.

10. Kris-Etherton PM, Yu S. Individual influences on serum lipid and lipoproteins: human studies. Am J Clin Nutr. 1997; 65:1628S–1644S.

11. Mensink RP, Katan MB. Effects of dietary fatty acids on serum lipids and lipoproteins: a meta-analysis of 27 trials. Arterioscler Thromb. 1992; 12:911–919.

12. Katan MB, Zock PL, Mensink RP. Trans fatty acids and their effects on lipoproteins in humans. Annu Rev Nutr. 1995; 15:473–493.

13. Harris WS, Park Y, Isley WL. Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol. 2003; 14:9–14.

14. U.S. Department of Health and Human Services. Food and Drug Administration. Food labeling: health claims: soluble fiber from certain foods and coronary heart disease: final rule. Fed Regist. 1998; 63:8103–8121.

15. Knopp RH, Walen CE, Retzlaff BM, McCann BS, Dowdy AA, Albers JJ, Gey GO, Cooper MN. Long-term cholesterol-lowering effectsof 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men: the dietary alternatives study. JAMA. 1997; 278:1509–1515.

16. Dufour MC. If you drink alcoholic beverages do so in moderation: what does this mean? J Nutr. 2001; 131:552S–561S.

17. Dufaux B, Order U, Muller R, et al. Delayed effects of prolonged exercise on serum lipoproteins. Metabolism. 1986; 35:105–109.

18. Wood PD, et al. Changes in Plasma lipids and lipoproteins in overweight men during weight loss through dieting and compared with exercise. N Engl J Med. 1988; 319:1173–1179.

19. Tran ZV, et al. The effects of exercise on blood lipids and lipoproteins. Med Sci Sports Exerc. 1983; 15:393–402.

20. Berg A, Frey I, et al. Physical Activity and lipoprotein lipid disorders. Sports Med. 1994; 17:6–21.

21. Williams PT, Krauss RM. Changes in lipoprotein subfractions during diet-induced and exercise induced weight loss in moderately overweight men. Circulation. 1990; 81:1293–1304.

22. Debusk RF, et al. Traing effects of long versus shout bouts of exercise in health subjects. Am J Cardiol. 1990; 65:1010–1013.

23. Tran ZV, Weltman A. Differential effects of exercise on serum lipid and lipoprotein levels seen with changes in body weight. JAMA. 1985; 254:919–924.

24. Thompson PD. In: Exercise & Sports Cardiology. McGraw-Hill; 2001.

25. Dowling EA. How Exercise Affects Lipid Profiles in Women. Phys Sportsmed. 2001; 29:45–52.

26. Kraus WE, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002; 347:1483–1489.

27. Durstine JL, Haskell WL. Effects of exercise training on plasma lipids and lipoproteins. Exerc Sport Sci Rev. 1994; 22:477–521.

28. Kokkinos PF, et al. Miles run per week and high-density lipoprotein cholesterol levels in healthy, middle-aged men. Arch Intern Med. 1995; 155:415–420.

29. Haffner SM, Lehto S, Rönnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229–234.

30. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002; 324:939–942.

31. Newman H, Colagiuri S, Chen M, Colagiuri R. Evidence Based Guidelines for Type 2 Diabetes: Macrovascular disease. Canberra: Diabetes Australia & NHMRC; 2004. http://www.diabetesaustralia.com.au.

32. Best J, Colagiuri S, Chen M, Colagiuri R. Evidence Based Guidelines for Type 2 Diabetes: Lipid Control. Canberra: Diabetes Australia & NHMRC; 2004. http://www.diabetesaustralia.com.au.

33. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2003; 27 Suppl. 2:S58–S65.

34. McIntosh A, Hutchinson A, Feder G, Durrington P, Elkeles R, Hitman GA, et al. Clinical guidelines and evidence review for Type 2 diabetes: Lipids Management. Sheffield: ScHARR, University of Sheffield; 2002. http://www.nice.org.uk/pdf/lipidsfull_guideline.pdf.

35. Scottish Intercollegiate Guidelines Network. SIGN 55. Management of Diabetes. 2001. http://www.sign.ac.uk.

36. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular diseases: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28:88–136.

37. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003; 361:2005–2016.

38. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multicentre randomized controlled trial. Lancet. 2004; 364:685–696.

39. Stevens R, Kothari V, Adler AI, Stratton IM, Holman RR. UKPDS 56: The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes. Clin Sci. 2001; 101:671–679.

40. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA. 1992; 268:1292–1300.

41. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial HOT Study Group. Lancet. 1998; 351:1755–1762.

42. Eccles M, Freemantle N, Mason J. North of England evidence based guidelines development project: Evidence based clinical practice guideline: aspirin for the secondary prophylaxis of vascular disease in primary care. BMJ. 1998; 316:1303–1309.

43. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71–78.

44. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med. 2003; 348:383–393.

45. Lim S. In: Symposium : Korean Longitudinal Study on Health and Aging. Korean society of lipidology and atherosclerosis; 2006.

46. Kreisberg RA, Kasim S. Cholesterol metabolism and aging. Am J Med. 1987; 82(1B):54–60.

47. Aronow W. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 2001; 56A(3):M138–M145.

48. Ducharme N, Radhamma R. Hyperlipidemia in the Elderly. Clin Geriatr Med. 2008; 3:471–487.

49. Geriatric medicine. National teacher training center of college of medicine Seoul national university; 2003. pp. 59.

50. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002; 288:462–467.

51. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002; 288:455–461.